Matches in SemOpenAlex for { <https://semopenalex.org/work/W1543679384> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- W1543679384 endingPage "P104" @default.
- W1543679384 startingPage "P104" @default.
- W1543679384 abstract "Major upper gastrointestinal bleeding leads to increased length of stay and increased risk of death among critically ill patients [1]. Despite recent developments in prophylaxis, large randomized trials have not shown a decrease in mortality. Patients with multiple system organ failure (MSOF) accompanied by coagulopathy are among those with high risk for clinically important major gastrointestinal bleeding. The combination of increased risk of gastrointestinal lesions and coagulopathy makes this population of critically ill extremely vulnerable once the bleeding begins. Recombinant activated factor VII (NovoSeven®; Novo Nordisk, Denmark) has recently been used to reduce bleeding complications and to control bleeding in hemophilic patients [2], and also in cases of intractable postsurgical intra-abdominal hemorrhage and traumatic bleeding. Fifteen surgical and nonsurgical patients with clinically significant gastrointestinal bleeding and MSOF (Simplified Acute Physiology Score II between 53 and 69 points) were enrolled in this study. All patients had different types and degrees of coagulation abnormalities before the bleeding episode as a part of their MSOF. After the onset of bleeding all patients required fluid resuscitation, red blood cell transfusion, fresh frozen plasma and platelet concentrates, and in 73% we used inotropes and pressors to support the failing circulation. The initial bleeding rate among patients was between 14 and 22 ml/min. After the bleeding was considered clinically significant we used a single standard intravenous dose of rFVIIa along with other standard accepted therapeutic measures, including endoscopy. Bleeding decreased after this first dose of rFVIIa and ceased within a period of 18–110 min, with progressive return of coagulation parameters to near pre-bleeding values. Four patients required a second dose of rFVIIa. There were no thromboembolic adverse effects and recurrent episodes of bleeding within the first 5 days after the bleeding episode. We concluded the successful use of rFVIIa in patients with MSOF and acute upper gastrointestinal bleeding, when this hemostatic agent could compensate for MSOF-related coagulation abnormalities. Further large studies are needed to assess the efficacy of rFVIIa use and its relationship with possible decreased transfusion requirements in such patients." @default.
- W1543679384 created "2016-06-24" @default.
- W1543679384 creator A5016415900 @default.
- W1543679384 creator A5032501277 @default.
- W1543679384 creator A5039250747 @default.
- W1543679384 creator A5069971590 @default.
- W1543679384 date "2003-01-01" @default.
- W1543679384 modified "2023-10-18" @default.
- W1543679384 cites W2116612251 @default.
- W1543679384 cites W85154878 @default.
- W1543679384 doi "https://doi.org/10.1186/cc1993" @default.
- W1543679384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3301549" @default.
- W1543679384 hasPublicationYear "2003" @default.
- W1543679384 type Work @default.
- W1543679384 sameAs 1543679384 @default.
- W1543679384 citedByCount "0" @default.
- W1543679384 crossrefType "journal-article" @default.
- W1543679384 hasAuthorship W1543679384A5016415900 @default.
- W1543679384 hasAuthorship W1543679384A5032501277 @default.
- W1543679384 hasAuthorship W1543679384A5039250747 @default.
- W1543679384 hasAuthorship W1543679384A5069971590 @default.
- W1543679384 hasBestOaLocation W15436793841 @default.
- W1543679384 hasConcept C512399662 @default.
- W1543679384 hasConcept C71924100 @default.
- W1543679384 hasConceptScore W1543679384C512399662 @default.
- W1543679384 hasConceptScore W1543679384C71924100 @default.
- W1543679384 hasIssue "Suppl 2" @default.
- W1543679384 hasLocation W15436793841 @default.
- W1543679384 hasLocation W15436793842 @default.
- W1543679384 hasOpenAccess W1543679384 @default.
- W1543679384 hasPrimaryLocation W15436793841 @default.
- W1543679384 hasRelatedWork W1506200166 @default.
- W1543679384 hasRelatedWork W1995515455 @default.
- W1543679384 hasRelatedWork W2039318446 @default.
- W1543679384 hasRelatedWork W2048182022 @default.
- W1543679384 hasRelatedWork W2080531066 @default.
- W1543679384 hasRelatedWork W2748952813 @default.
- W1543679384 hasRelatedWork W2899084033 @default.
- W1543679384 hasRelatedWork W3031052312 @default.
- W1543679384 hasRelatedWork W3032375762 @default.
- W1543679384 hasRelatedWork W3108674512 @default.
- W1543679384 hasVolume "7" @default.
- W1543679384 isParatext "false" @default.
- W1543679384 isRetracted "false" @default.
- W1543679384 magId "1543679384" @default.
- W1543679384 workType "article" @default.